Kite Pharma expands CAR-T deal with Sourasky Medical Center

26 January 2015

US clinical-stage biopharma company Kite Pharma (Nasdaq: KITE), focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to chimeric antigen receptor (CAR) T cell therapy, the technology underlying Kite's most advanced programs in cancer immunotherapy.

Under the agreement, Kite will collaborate with Zelig Eshhar, the leading pioneer in CAR T cell research and Chair of Immunology Research within the Tel Aviv Sourasky Medical Center's Division of R&D.

"Zelig's award-winning research has been at the center of CAR-T cell programs currently advancing in clinical studies….We believe this collaboration will facilitate continued development and advancement of novel, efficacious, and more selective CAR-T cell products for various tumor types," said Arie Belldegrun, Kite Pharma's president and chief executive.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK